Greenstone LLC, a wholly owned subsidiary of Pfizer Inc.,  announced that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg tablets (100-count bottle) and Finasteride 5mg tablets (90-count bottle), both distributed in the US market. The recall is due to the possibility that incorrect labels has been placed on the bottles by a third-party manufacturer. This is the only lot number being recalled and no other lots or markets are believed to be impacted.

Importantly, bottles labelled as Citalopram Lot FI0510058-A may contain Finasteride. Patients who believe they may have ingested the wrong medication should contact their physician as soon as possible. Women who are, or may become pregnant, should not take or handle Finasteride due to the possible risk of side effects which may cause abnormalities to the external genitalia of a developing male foetus. Citalopram is contraindicated in patients taking Mono-Amine Oxidase Inhibitors (MAOIs) or pimozide, It is also contraindicated in patients with a hypersensitivity to Citalopram or any of the inactive ingredients in the tablet. Patients who discontinue Citalopram abruptly by inadvertently taking the mislabelled product may experience discontinuation symptoms and/or worsening of depression.

Bottles of either Citalopram (used to treat depression) or Finasteride (for the treatment of benign prostatic hyperplasia) with lot number FI050058-A should be returned to the pharmacist.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Also, any adverse events that may be related to the use of these products should be reported to Pfizer Inc. at-1-800-438-1985 (24 hours a day) or to FDA's Med watch programme either online, by regular mail or by fax.